Letter to BS: Pharma industry, pharmacists also deserve appreciation

India has the potential to develop an antidote to Covid-19

drug, medicine, drugs, pharma, pharmaceutical
The government of India should empower our pharmaceutical scientists and doctors, provide them with more infrastructure
Business Standard
2 min read Last Updated : May 05 2020 | 11:28 PM IST
Governments across the world are engaged in an intense battle to contain the Covid-19 pandemic. Only a vaccine can be a definite and conclusive solution to help mankind return to normal life. Whoever first develops a Covid vaccine will gain a huge competitive advantage. India has the potential to develop an antidote to Covid-19. We should be proud of our biotech companies. Six Indian companies are in race to make a vaccine for Covid. One of them, Serum Institute of India (SII), is the world's largest vaccine manufacturer by the number of doses produced and sold globally — more than 1.5 billion so far. It is great to know that a vaccine candidate, developed by the SII in partnership with American biotechnology firm Codagenix, has progressed to the pre-clinical test phase (the animal trial phase) and estimated to be ready by early 2022.

The government of India should empower our pharmaceutical scientists and doctors, provide them with more infrastructure. We should also enhance our bio-defence mechanism. Hospitals should be equipped well to treat patients affected with special pathogens in future. In this crisis, pharma industries and pharmacists also deserve appreciation. They have been working tirelessly.

Ravi Teja Kathuripalli  Hyderabad

Letters can be mailed, faxed or e-mailed to: 
The Editor, Business Standard
Nehru House, 4 Bahadur Shah Zafar Marg 
New Delhi 110 002 
Fax: (011) 23720201  ·  E-mail: letters@bsmail.in
All letters must have a postal address and telephone number

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusLockdownPharma sectorBiotechnology

Next Story